Gd-EOB-DTPA增强核磁与CDT1蛋白在肝细胞癌诊疗中的研究进展
Research Progress of Gd-EOB-DTPA-Enhanced Nuclear Magnetic Resonance and CDT1 Protein in the Diagnosis and Treatment of Hepatocellular Carcinoma
DOI: 10.12677/ACM.2023.13102285, PDF,   
作者: 赵亚龙：青海大学临床医学院，青海 西宁；温生宝*：青海大学附属医院影像中心，青海 西宁
关键词: 肝细胞癌；CDT1；Gd-EOB-DTPA；磁共振成像；相关性；Hepatocellular Carcinoma； CDT1； Gd-EOB-DTPA； Magnetic Resonance Imaging； Correlation
摘要: 肝细胞癌(hepatocellular carcinoma, HCC)具有高发病率及死亡率、预后差的临床特点。为控制不良的临床结果及改善早期诊断和治疗方法，我们必须在细胞水平上加深对肝细胞癌的了解。CDT1在肝细胞癌的发生、发展和预后方面发挥了重要作用，有望成为潜在的肝细胞癌生物标志物。本文概述了CDT1在DNA复制起始中的功能以及其在肿瘤发生和发展中的作用，着重讨论了CDT1在肝细胞癌中的表达情况。此外，还总结了Gd-EOB-DTPA增强核磁共振成像的基本原理及其在肝细胞癌诊断、分化程度和预后评估中的应用，强调了其无创性和定量分析方法。最后，我们推测了Gd-EOB-DTPA核磁共振与肝细胞癌CDT1表达的相关性：作为一种无创性手段，Gd-EOB-DTPA MR对术前预测肝细胞癌CDT1的表达具有极大的应用价值。
Abstract: Hepatocellular carcinoma (HCC) is characterized by high morbidity, mortality and poor prognosis. In order to control adverse clinical outcomes and improve early diagnosis and treatment, we must deepen our understanding of hepatocellular carcinoma at the cellular level. CDT1 plays an im-portant role in the occurrence, development and prognosis of hepatocellular carcinoma, and is ex-pected to become a potential biomarker of hepatocellular carcinoma. This article summarizes the function of CDT1 in the initiation of DNA replication and its role in tumorigenesis and development, with emphasis on the expression of CDT1 in hepatocellular carcinoma. In addition, the basic princi-ple of Gd-EOB-DTPA-enhanced magnetic resonance imaging and its application in the diagnosis, dif-ferentiation and prognosis of hepatocellular carcinoma were summarized, and its non- invasive and quantitative methods were emphasized. Finally, we speculated the correlation between Gd-EOB-DTPA NMR and the expression of CDT1 in hepatocellular carcinoma: as a non-inva- sive method, Gd-EOB-DTPAMR has great application value in predicting the expression of CDT1 in hepa-tocellular carcinoma before operation.
文章引用：赵亚龙, 温生宝. Gd-EOB-DTPA增强核磁与CDT1蛋白在肝细胞癌诊疗中的研究进展[J]. 临床医学进展, 2023, 13(10): 16332-16338. https://doi.org/10.12677/ACM.2023.13102285

参考文献

[1] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版) [J]. 临床肝胆病杂志, 2022, 38(2): 288-303.
[2] Llovet, J.M., Kelley, R.K., Villanueva, A., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[3] Cai, C., Zhang, Y., Hu, X., et al. (2021) CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article ID: 721644. [Google Scholar] [CrossRef] [PubMed]
[4] Jiang, Z., Wei, Z., Chen, J., et al. (2022) BZW2, CDT1 and IVD Act as Biomarkers for Predicting Hepatocellular Carcinoma. Current Cancer Drug Targets.
[5] Yu, Z., Wang, R., Chen, F., et al. (2018) Five Novel Oncogenic Signatures Could Be Utilized as AFP-Related Diagnostic Biomarkers for Hepatocellular Carcinoma Based on Next-Generation Sequencing. Digestive Diseases and Sciences, 63, 945-957. [Google Scholar] [CrossRef] [PubMed]
[6] Dube, J.P., Azzi, Z., Semionov, A., et al. (2019) Imaging of Post Transthoracic Needle Biopsy Complications. The Canadian Association of Radiologists Journal, 70, 156-163. [Google Scholar] [CrossRef] [PubMed]
[7] Tian, G., Kong, D., Jiang, T., et al. (2020) Complications after Per-cutaneous Ultrasound-Guided Liver Biopsy: A Systematic Review and Meta-Analysis of a Population of More than 12,000 Patients from 51 Cohort Studies. Journal of Ultrasound in Medicine, 39, 1355-1365. [Google Scholar] [CrossRef] [PubMed]
[8] Chen, Y., Qin, X., Long, L., et al. (2020) Diagnostic Value of Gd-EOB-DTPA-Enhanced MRI for the Expression of Ki67 and Microvascular Density in Hepatocellular Carcinoma. Journal of Magnetic Resonance Imaging, 51, 1755-1763. [Google Scholar] [CrossRef] [PubMed]
[9] Maslowska, K.H., Makiela-Dzbenska, K., Mo, J.Y., et al. (2018) High-Accuracy Lagging-Strand DNA Replication Mediated by DNA Polymerase Dissociation. Proceedings of the Na-tional Academy of Sciences of the United States of America, 115, 4212-4217. [Google Scholar] [CrossRef] [PubMed]
[10] Costa, A. and Diffley, J.F.X. (2022) The Initiation of Eukaryotic DNA Replication. Annual Review of Biochemistry, 91, 107-131. [Google Scholar] [CrossRef] [PubMed]
[11] Guerrero-Puigdevall, M., Fernandez-Fuentes, N. and Frigola, J. (2021) Stabilisation of Half MCM Ring by Cdt1 during DNA Insertion. Nature Communications, 12, Ar-ticle No. 1746. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, H. (2021) Regulation of DNA Replication Licensing and Re-Replication by Cdt1. International Journal of Molecular Sciences, 22, Article No. 5195. [Google Scholar] [CrossRef] [PubMed]
[13] Karantzelis, N., Petropoulos, M., De Marco, V., et al. (2022) Small Molecule Inhibitor Targeting CDT1/Geminin Protein Complex Promotes DNA Damage and Cell Death in Cancer Cells. Frontiers in Pharmacology, 13, Article ID: 860682. [Google Scholar] [CrossRef] [PubMed]
[14] Rona, G. and Pagano, M. (2023) CDT1, a Licensing Factor That Limits Rereplication. Molecular Cell, 83, 1-3. [Google Scholar] [CrossRef] [PubMed]
[15] Lin, Y.C. and Prasanth, S.G. (2021) Replication Initiation: Im-plications in Genome Integrity. DNA Repair, 103, Article ID: 103131. [Google Scholar] [CrossRef] [PubMed]
[16] Houben, R., Ebert, M., Hesbacher, S., et al. (2020) Merkel Cell Polyomavirus Large T Antigen Is Dispensable in G2 and M-Phase to Promote Proliferation of Merkel Cell Carcinoma Cells. Viruses, 12, Article No. 1162. [Google Scholar] [CrossRef] [PubMed]
[17] Liontos, M., Koutsami, M., Sideridou, M., et al. (2007) Deregulated Overexpression of hCdt1 and hCdc6 Promotes Malignant Behavior. Cancer Research, 67, 10899-10909. [Google Scholar] [CrossRef] 
[18] Siril, Y.J., Kouketsu, A., Oikawa, M., et al. (2019) Im-munohistochemical Assessment of Chromatin Licensing and DNA Replication Factor 1, Geminin, and Gamma-H2A.X in Oral Epithelial Precursor Lesions and Squamous Cell Carcinoma. Journal of Oral Pathology & Medicine, 48, 888-896. [Google Scholar] [CrossRef] [PubMed]
[19] Mahadevappa, R., Neves, H., Yuen, S.M., et al. (2017) The Prognostic Significance of Cdc6 and Cdt1 in Breast Cancer. Scientific Reports, 7, Article No. 985. [Google Scholar] [CrossRef] [PubMed]
[20] Wang, C., Che, J., Jiang, Y., et al. (2022) CDT1 Facilitates Me-tastasis in Prostate Cancer and Correlates with Cell Cycle Regulation. Cancer Biomarkers, 34, 459-469. [Google Scholar] [CrossRef] 
[21] Petropoulos, M., Champeris, T.S., Nikou, S., et al. (2022) Cdt1 Over-expression Drives Colorectal Carcinogenesis through Origin Overlicensing and DNA Damage. The Journal of Pathology, 259, 10-20. [Google Scholar] [CrossRef] [PubMed]
[22] 饶圣祥, 胡道予, 宦怡, 等. 肝胆特异性MRI对比剂钆塞酸二钠临床应用专家共识[J]. 临床肝胆病杂志, 2016, 32(12): 2236-2241.
[23] Inchingolo, R., Faletti, R., Grazioli, L., et al. (2018) MR with Gd-EOB-DTPA in Assessment of Liver Nodules in Cirrhotic Patients. World Journal of Hepa-tology, 10, 462-473. [Google Scholar] [CrossRef] [PubMed]
[24] Li, J., Wang, J., Lei, L., et al. (2019) The Diag-nostic Performance of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging and Contrast-Enhanced Mul-ti-Detector Computed Tomography in Detecting Hepatocellular Carcinoma: A Meta-Analysis of Eight Prospective Stud-ies. European Radiology, 29, 6519-6528. [Google Scholar] [CrossRef] [PubMed]
[25] Murakami, T., Sofue, K. and Hori, M. (2022) Diagnosis of Hepatocellular Carcinoma Using Gd-EOB-DTPA MR Imaging. Magnetic Resonance in Medical Sciences, 21, 168-181. [Google Scholar] [CrossRef] [PubMed]
[26] Motosugi, U., Bannas, P., Sano, K., et al. (2015) Hepatobiliary MR Contrast Agents in Hypovascular Hepatocellular Carcinoma. Journal of Magnetic Resonance Imaging, 41, 251-265. [Google Scholar] [CrossRef] [PubMed]
[27] Choi, J.Y., Lee, J.M. and Sirlin, C.B. (2014) CT and MR Imaging Diagno-sis and Staging of Hepatocellular Carcinoma: Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. Radiology, 273, 30-50. [Google Scholar] [CrossRef] [PubMed]
[28] Ding, F., Huang, M., Ren, P., et al. (2023) Quantitative Information from Gadobenate Dimeglumine-Enhanced MRI Can Predict Proliferative Subtype of Solitary Hepatocellular Carcinoma: A Multicenter Retrospective Study. European Radiology. [Google Scholar] [CrossRef] [PubMed]
[29] Ichikawa, S., Morisaka, H., Omiya, Y., et al. (2022) Distinction between Hepatocellular Carcinoma and Hypervascular Liver Metastases in Non-Cirrhotic Patients Using Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging. The Canadian Association of Radiologists Journal, 73, 639-646. [Google Scholar] [CrossRef] [PubMed]
[30] Semaan, S., Vietti Violi, N., Lewis, S., et al. (2020) Hepatocel-lular Carcinoma Detection in Liver Cirrhosis: Diagnostic Performance of Contrast-Enhanced CT vs. MRI with Extracel-lular Contrast vs. Gadoxetic Acid. European Radiology, 30, 1020-1030. [Google Scholar] [CrossRef] [PubMed]
[31] Haimerl, M., Utpatel, K., Gotz, A., et al. (2021) Quantification of Contrast Agent Uptake in the Hepatobiliary Phase Helps to Differentiate Hepatocellular Carcinoma Grade. Scientific Re-ports, 11, Article No. 22991. [Google Scholar] [CrossRef] [PubMed]
[32] 莫志英, 廖锦元. 钆塞酸二钠增强MRI肝胆期评估肝细胞癌分化程度的价值[J]. 医学影像学杂志, 2022, 32(8): 1301-1305.
[33] Yang, T., Wei, H., Wu, Y., et al. (2023) Pre-dicting Histologic Differentiation of Solitary Hepatocellular Carcinoma Up to 5 cm on Gadoxetate Disodium-Enhanced MRI. Insights Imaging, 14, Article No. 3. [Google Scholar] [CrossRef] [PubMed]
[34] Peng, Z., Jiang, M., Cai, H., et al. (2016) Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging Combined with T1 Mapping Predicts the Degree of Differenti-ation in Hepatocellular Carcinoma. BMC Cancer, 16, Article No. 625. [Google Scholar] [CrossRef] [PubMed]
[35] Choi, S.Y., Kim, S.H., Park, C.K., et al. (2018) Imaging Features of Gadoxetic Acid-Enhanced and Diffusion-Weighted MR Imaging for Identifying Cytokeratin 19-Positive Hepatocellu-lar Carcinoma: A Retrospective Observational Study. Radiology, 286, 897-908. [Google Scholar] [CrossRef] [PubMed]
[36] 陈闯, 何健, 伏旭, 等. 术前普美显增强核磁共振成像对肝细胞癌微血管侵犯的预测价值[J]. 中国普通外科杂志, 2022, 31(7): 896-904.
[37] Min, J.H., Lee, M.W., Park, H.S., et al. (2020) Interobserver Variability and Diagnostic Performance of Gadoxetic Acid-Enhanced MRI for Predicting Mi-crovascular Invasion in Hepatocellular Carcinoma. Radiology, 297, 573-581. [Google Scholar] [CrossRef] [PubMed]
[38] Yang, Y., Fan, W., Gu, T., et al. (2021) Radiomic Features of Multi-ROI and Multi-Phase MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma. Frontiers in Oncology, 11, Article ID: 756216. [Google Scholar] [CrossRef] [PubMed]
[39] Liu, Z., Yang, S., Chen, X., et al. (2022) Nomogram Development and Validation to Predict Ki-67 Expression of Hepatocellular Carcinoma Derived from Gd-EOB-DTPA-Enhanced MRI Combined with T1 Mapping. Frontiers in Oncology, 12, Article ID: 954445. [Google Scholar] [CrossRef] [PubMed]
[40] Yan, Y., Lin, X.S., Ming, W.Z., et al. (2023) Radiomic Analysis Based on Gd-EOB-DTPA Enhanced MRI for the Preoperative Prediction of Ki-67 Expression in Hepatocellular Carci-noma. Academic Radiology. [Google Scholar] [CrossRef] [PubMed]

为你推荐